Tiny sponges offer a big new net for biomarkers

A microsponge crafted from seaweed has become the "dirt cheap" basis for a new tool that can snare a wide range of biomarkers, a new approach aimed at accelerating and improving the diagnosis of cancer and other diseases.

Investigators at Rice say that agarose makes a perfect nano-net that can sweep up everything from big protein biomarkers to drug metabolites in blood and other types of body fluids. "We create an ultrahigh-surface-area microsponge that collects a large amount of material," Professor John McDevitt tells Fast Company. "The sponge is like a jellyfish with tentacles that capture the biomarkers."

By spreading a wider net than current diagnostics, McDevitt hopes to deliver new technology that can swiftly deliver a big payload of information on a person's health, whether they're in a hospital or in the streets. And, he adds, they should be far superior in helping identify early-stage diseases, giving physicians the information they need to start treatment when it can do the most good. Rice is now hosting six clinical trials to test the technology.

- check out the release
- here's the story from Fast Company

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.